financetom
Business
financetom
/
Business
/
Moleculin Biotech to Raise $6 Million From Exercise of Warrants; Shares Fall Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Moleculin Biotech to Raise $6 Million From Exercise of Warrants; Shares Fall Pre-Bell
Aug 28, 2025 6:20 AM

08:57 AM EDT, 08/28/2025 (MT Newswires) -- Moleculin Biotech ( MBRX ) said Thursday that some holders of the company's outstanding warrants have agreed to exercise them to buy about $6 million worth of common shares.

Certain holders of the warrants will buy about 16.2 million common shares of the company originally issued in June at $0.37 apiece, Moleculin Biotech ( MBRX ) said.

The transaction is expected to close on or about Thursday with net proceeds expected to be used for working capital and general corporate purposes, the biotech company said.

Shares were down over 37% in recent Thursday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Performance Food Group Attracts Takeover Interest From US Foods
Market Chatter: Performance Food Group Attracts Takeover Interest From US Foods
Jul 11, 2025
07:16 AM EDT, 07/11/2025 (MT Newswires) -- Performance Food Group ( PFGC ) has drawn takeover interest from peer US Foods Holding ( USFD ) for a potential deal that would establish a food distribution company with about $100 billion of combined sales, Bloomberg News reported Friday, citing people familiar with the matter said. US Foods ( USFD ) has...
Capricor Therapeutics Says FDA Requires Additional Data on Deramiocel; Shares Fall Pre-Bell
Capricor Therapeutics Says FDA Requires Additional Data on Deramiocel; Shares Fall Pre-Bell
Jul 11, 2025
07:17 AM EDT, 07/11/2025 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said Friday that the US Food and Drug Administration has required additional clinical data on deramiocel, a cell therapy candidate for cardiomyopathy in Duchenne muscular dystrophy patients. The company said it received FDA's complete response letter, saying the agency had completed its review of Capricor's biologics license application...
Virtus Investment Partners Posts Higher Preliminary Assets Under Management in June
Virtus Investment Partners Posts Higher Preliminary Assets Under Management in June
Jul 11, 2025
07:19 AM EDT, 07/11/2025 (MT Newswires) -- Virtus Investment Partners ( VRTS ) said Friday its preliminary assets under management increased to $170.71 billion as of June 30, up from $167.60 billion a month earlier. The increase can be attributed to market performance and positive net flows in exchange-traded funds, partially offset by net outflows in institutional accounts, US retail...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved